Previous Close | 249.62 |
Open | 251.10 |
Bid | 252.00 x 800 |
Ask | 255.09 x 800 |
Day's Range | 250.50 - 257.00 |
52 Week Range | 207.33 - 276.69 |
Volume | 2,272,190 |
Avg. Volume | 2,765,598 |
Market Cap | 147.238B |
Beta (5Y Monthly) | 0.74 |
PE Ratio (TTM) | 20.77 |
EPS (TTM) | 12.31 |
Earnings Date | Apr 28, 2021 - May 03, 2021 |
Forward Dividend & Yield | 7.04 (2.75%) |
Ex-Dividend Date | May 14, 2021 |
1y Target Est | 255.93 |
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.
Amgen has been in a long-term uptrend but the stock has been stalled for the past year. The indicators I favor are looking more positive so let's check out the charts to see if this is the time to buy.